Chiome Bioscience Inc. Statistics
Want to see JP:4583 full AI Analyst Report?
Chiome Bioscience Inc. (4583) Stock Statistics & Valuation Metrics
Total Valuation
Chiome Bioscience Inc. has a market cap or net worth of JPY 6.06B. The enterprise value is JPY 4.67B.
- Market Cap
- JPY 6.06B
- Enterprise Value
- JPY 4.67B
Share Statistics
Chiome Bioscience Inc. has 81,863,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 81,863,700
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Chiome Bioscience Inc.’s return on equity (ROE) is -0.88 and return on invested capital (ROIC) is -68.07%.
- Return on Equity (ROE)
- -0.88
- Return on Assets (ROA)
- -0.57
- Return on Invested Capital (ROIC)
- -68.07%
- Return on Capital Employed (ROCE)
- -0.72
- Revenue Per Employee
- 12.11M
- Profits Per Employee
- -20.06M
- Employee Count
- 49
- Asset Turnover
- 0.34
- Inventory Turnover
- 4.81
Valuation Ratios
The current PE Ratio of Chiome Bioscience Inc. is -6.10. Chiome Bioscience Inc.’s PEG ratio is -0.38.
- PE Ratio
- -6.10
- PS Ratio
- 10.55
- PB Ratio
- 3.87
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- -0.38
Income Statement
In the last 12 months, Chiome Bioscience Inc. had revenue of 593.29M and earned -982.78M in profits. Earnings per share was -14.47.
- Revenue
- 593.29M
- Gross Profit
- 355.58M
- Operating Income
- -979.77M
- Pretax Income
- -979.54M
- Net Income
- -982.78M
- EBITDA
- -972.64M
- Earnings Per Share (EPS)
- -14.47
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Chiome Bioscience Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -15.68%
Stock Price Statistics
- Beta
- 0.75
- 52-Week Price Change
- -44.78%
- 50-Day Moving Average
- 93.72
- 200-Day Moving Average
- 91.56
- Relative Strength Index (RSI)
- 27.11
- Average Volume (3m)
- 1.65M
Important Dates
Chiome Bioscience Inc. upcoming earnings date is Nov 10, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 10, 2026
- Ex-Dividend Date
- ―
Financial Position
Chiome Bioscience Inc. as a current ratio of 4.13, with Debt / Equity ratio of 23.32%
- Current Ratio
- 4.13
- Quick Ratio
- 3.99
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- 0.97
- Interest Coverage Ratio
- -310.55
Taxes
In the past 12 months, Chiome Bioscience Inc. has paid 3.24M in taxes.
- Income Tax
- 3.24M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Chiome Bioscience Inc. EV to EBITDA ratio is -5.52, with an EV/FCF ratio of 0.00.
- EV to Sales
- 8.17
- EV to EBITDA
- -5.52
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Chiome Bioscience Inc. has JPY 1.37B in cash and marketable securities with JPY 67.50M in debt, giving a net cash position of JPY 1.30B billion.
- Cash & Marketable Securities
- JPY 1.37B
- Total Debt
- JPY 67.50M
- Net Cash
- JPY 1.30B
- Net Cash Per Share
- JPY 15.94
- Tangible Book Value Per Share
- JPY 20.69
Margins
Gross margin is 61.00%, with operating margin of -149.99%, and net profit margin of -150.49%.
- Gross Margin
- 61.00%
- Operating Margin
- -149.99%
- Pretax Margin
- -149.96%
- Net Profit Margin
- -150.49%
- EBITDA Margin
- -148.01%
- EBIT Margin
- -149.41%
Analyst Forecast
The average price target for Chiome Bioscience Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -19.99%
- EPS Growth Forecast
- 16.36%
Scores
- Smart Score
- ―
- AI Score
- 49
